Evidence map›Paper›PMID 37752429›Full record

ArticleBMC neurology2023

Obstructive sleep apnea: a major risk factor for COVID-19 encephalopathy?

Gautier Breville, François Herrmann, Dan Adler, Christine Deffert, Giulia Bommarito, Patrick Stancu, Alice Accorroni, Marjolaine Uginet, Frederic Assal, Renaud Tamisier and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 3 countries.

Gautier BrevilleDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA. gautier.breville@pennmedicine.upenn.edu.
François HerrmannDepartment of Rehabilitation and Geriatrics, Division of Geriatrics, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Dan AdlerDivision of Pneumology, La Tour Hospital, Geneva, Switzerland.
Christine DeffertLaboratory of Biological Fluids, Laboratory Medicine Division, Diagnostic Department, Geneva University Hospitals, Geneva, Switzerland.
Giulia BommaritoLeenaards Memory Center, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Patrick StancuDepartment of Neurosciences, Division of Neurology, Geneva University Hospitals, Geneva, Switzerland.
Alice AccorroniDepartment of Neurosciences, Division of Neurology, Geneva University Hospitals, Geneva, Switzerland.
Marjolaine UginetDepartment of Neurosciences, Division of Neurology, Geneva University Hospitals, Geneva, Switzerland.
Frederic AssalDepartment of Neurosciences, Division of Neurology, Geneva University Hospitals, Geneva, Switzerland.
Renaud TamisierUniv. Grenoble Alpes, INSERM, CHU Grenoble Alpes, HP2, 38000, Grenoble, France.
Patrice H LaliveDepartment of Neurosciences, Division of Neurology, Geneva University Hospitals, Geneva, Switzerland.
Jean-Louis PepinDivision of Pneumology, La Tour Hospital, Geneva, Switzerland.
Karl-Olof LövbladDivision of Neuroradiology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Gilles AllaliDepartment of Neurosciences, Division of Neurology, Geneva University Hospitals, Geneva, Switzerland.
University Hospital of Geneva · CHUniversity of Geneva · CHCentre Hospitalier Universitaire de Grenoble · FRHôpital de la Tour · CHInserm · FRUniversity of Lausanne · CHUniversity of Pennsylvania · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study evaluates the impact of high risk of obstructive sleep apnea (OSA) on coronavirus disease 2019 (COVID-19) acute encephalopathy (AE).

methodsBetween 3/1/2020 and 11/1/2021, 97 consecutive patients were evaluated at the Geneva University Hospitals with a neurological diagnosis of COVID-19 AE. They were divided in two groups depending on the presence or absence of high risk for OSA based on the modified NOSAS score (mNOSAS, respectively ≥ 8 and < 8). We compared patients' characteristics (clinical, biological, brain MRI, EEG, pulmonary CT). The severity of COVID-19 AE relied on the RASS and CAM scores.

resultsMost COVID-19 AE patients presented with a high mNOSAS, suggesting high risk of OSA (> 80%). Patients with a high mNOSAS had a more severe form of COVID-19 AE (84.8% versus 27.8%), longer mean duration of COVID-19 AE (27.9 versus 16.9 days), higher mRS at discharge (≥ 3 in 58.2% versus 16.7%), and increased prevalence of brain vessels enhancement (98.1% versus 20.0%). High risk of OSA was associated with a 14 fold increased risk of developing a severe COVID-19 AE (OR = 14.52). DISCUSSION: These observations suggest an association between high risk of OSA and COVID-19 AE severity. High risk of OSA could be a predisposing factor leading to severe COVID-19 AE and consecutive long-term sequalae.

Indexed as

Brain DiseasesCOVID-19Sleep Apnea, ObstructiveHumansPolysomnographyRisk FactorsCOVID-19 encephalopathyObstructive sleep apneaSARS-CoV-2

Identifiers

PMID37752429
PMCPMC10523731
OpenAlexW4387034984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.